32 results about "Thrombotic thrombocytopenic purpura" patented technology

Compositions and methods are provided for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP), stroke and myocardial infarction.

The invention relates to a traditional Chinese medicine for treating thrombocytopenic purpura, which is characterized by comprising the following main components: 6g of deerhorn gelatin, 6g of tortoise shell gelatin, 10g of ass-skin glue, 15g of wintergreen, 15g of rhizoma drynariae, 15g of flastem milkvetch seed, 15g of yerbadetajo herba ecliptae, 30g of agrimony, 30g of hoantchy root, 15g of atractylodes macrocephaia, 15g of figwort, 15g of root bark of peony tree, 15g of forsythia, 9g of vermilion and the like. The preparation method comprises the following steps: placing the Chinese medical herbs into a container, adding water, decocting the Chinese medical herbs for 30min by slow fire, filtering residue and getting 300ml of decoction. The traditional Chinese medicine is taken after the breakfast, the lunch and the supper through warming by one dose one day for 5 doses in each period of treatment. The deerhorn gelatin, the tortoise shell gelatin and the ass-skin glue are molten by heat. The traditional Chinese medicine is prepared by pure Chinese medical herbs by adopting the traditional preparation method, maintains the property of the medicine, has the efficacy of nourishing the kidney, supplementing the marrow, invigorating the spleen, promoting the blood circulation, cooling the blood and dissolving the purpura and achieves the purpose of treatment without side effect.

The invention discloses a method for detecting the ADAAMTS13 enzyme activity in serum by SELDI-TOF-MS (surface-enhanced laser desorption/ionization-time of flight-mass spectrometry). The method comprises the following steps of (1) performing ADAAMTS13 enzyme digestion substrate GST-vWF73-6XHis recombination protein expression and purification; (2) taking an enzyme digestion reaction; (3) after an ADAAMTS13 enzyme digestion product is enriched by an IMAC chip, performing recognition and detection on the ADAAMTS13 enzyme digestion product; obtaining the enzyme digestion activity of ADAAMTS13 in the serum sample through analysis software. The detection method is fast and effective; the detection is precise; after the detection on all TMA (thrombotic microangiopathy) suspected cases, all cases with the ADAAMTS13 enzyme activity being less than 10 percent are screened out; the patients are treated as TTP (thrombotic thrombocytopenic purpura) patients. For all TTP cases, in the treatment process and the long-time monitoring after the hospital leaving, the regular detection of the ADAAMTS13 enzyme activity needs to be performed, so that the patient can be better and correctly treated; the treatment cost is reduced; the survival rate and the life quality of the patient are effectively improved.

The invention relates to a medicine for treating thrombocytopenic purpura and a preparation method thereof, belonging to the field of traditional Chinese medicines. The medicine comprises 30-90 weight parts of dry extract powder of selaginella moellendorfii and 10-70 weight parts of pharmaceutical adjuvant and is prepared into tablets, capsules, granules and pills by various methods. The preparation process is simple, the cost is low and the prepared preparations have excellent performance and stable quality and are convenient for the patients to take. Clinical trials show that the medicine can achieve better clinical results and has no obvious side effects when being applied to treating thrombocytopenic purpura and other hemorrhagic diseases.

The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of Astragalus membranaceus. The extracts are prepared from Astragalus membranaceus and can comprise, for example, an acid-modified arabinogalactan protein composition having an arabinose:galactose ratio ranging from about 3.5:1 to about 5.0:1, from about 5% to about 10% rhamnose, from about 15% to about 20% galactose, and from about 10% to about 15% glucose. The compositions can be used in the treatment of idiopathic thrombocytopenic purpura and the formulation of medicaments for such treatments.

The invention relates to a preparation for treating thrombocytopenic purpura caused by frenetic blood movement due to intense heat and a preparation method. The preparation is prepared from the following medicinal raw materials by weight percentage: 18-48% of radix rehmanniae, 9-24% of radix scrophulariae, 9-24% of rhizoma anemarrhenae, 9-24% of radix ophiopogonis, 6-15% of cortex moutan radicis,9-24% of lithospermum, 6-15% of radix scutellariae, 9-24% of honeysuckle, 9-24% of fructus forsythiae, 18-48% of gypsum, 9-24% of folium isatidis and 4-10% of raw liquorice. According to the preparation, active ingredients are extracted from the medicinal raw materials by a water boiling extraction method; the activity of the active ingredients is kept, so that the dissolubility of the active ingredients in the medicine can be greatly improved; medicine absorption is facilitated; and the bioavailability of the medicine can be improved. In addition, the medicine is a pure traditional Chinese medicine compound preparation, so that the medicine does not cause toxic or side effects and is good in safety after a patient takes the medicine for a long term. In addition, the preparation method ofthe medicine is simple in technology and convenient to operate.

The invention discloses an idiopathic thrombocytopenic purpura medicament composition. The medicament composition is prepared by active pharmaceutical ingredients including, by weight, 100-200 parts of Gynura segetum, 50-150 parts of forsythia, 100-200 parts of field thistle, 100-200 parts of rehmannia, 10-100 parts of fried gardenia, 50-100 parts of savatier monochasma and 50-150 parts of fried yams. A preparation method of the idiopathic thrombocytopenic purpura medicament composition includes steps of weighting the active pharmaceutical ingredients according to the formulas, evenly mixing the active pharmaceutical ingredients by grinding, extracting water and concentrating or the combination of the both, and then obtaining the medicament composition. The medicament composition is capable of cooling blood and stopping blood, clearing heat and removing toxicity, and is used for various hemorrhages caused by the heat forced blood line and the blood overflowing outside pulse such as bleeding gums, blood oozing out of nasals, skin purpura, hemafecia, hematuria and menorrhagia .

The invention provides a traditional Chinese medicine composition for inhibiting and removing aplatelet antibody and curing idiopathic thrombocytopenic purpura, wherein honeysuckle capable of clearing away heat and toxic materials and good at removing blood poisonis is taken as a monarch drug in a prescription, and is used to remove the platelet antibody in the blood. Radix rehmanniae, cortex moutan, red peony root and ligusticum wallichii are taken as an adjuvant drug, and are used to cool blood, clear heat, improve the internal environment of blood heat of a human body, and prevent and control the internal base for the generation of a blood platelet; lithospermum, madder, nodus nelumbinis rhizomatis charcoal and radix notoginseng powder are used to cool blood, remove blood stasis, stop bleeding and improve the signs and symptoms of bleeding; divaricate saposhnikovia root is used to dispel wind and clear heat, and is compatible with the honeysuckle to avoid relapse of the disease, caused by the reason that wind heat enters the interior. Liquorice is a conductant drug, relaxes tension, detoxifies, and coordinates the drug actions of the prescription. The various medicines in the prescription are combined, the prescription is simple but complete, is in great accuracy and hits the pathogenesis, and the various medicines play the roles of detoxifying, cooling blood, dispersing blood stasis, removing ecchymosis and nourishing spleen and kidney together, so that the bleeding of an ITP patient is reduced, and the various clinical symptoms are further alleviated.

The invention relates to the field of drug prescriptions, specifically a pettitoes soup with seven elements for curing idiopathic thrombocytopenic purpura. The drug comprises the following raw materials: pettitoes, spatholobus stem, rumex nepalensis, agrimony, licorice, peanut skin and jujube. The pettitoes are washed, chopped, and boiled with slices of the spatholobus stem, the agrimony, the licorice, the peanut skin and the jujube; after decoction, rumex nepalensis is added to mix evenly and slag is removed to get a filtrate which is put into a sterile glass bottle for use. The weight percentages of the raw materials are as follows: 25-36 percent of the pettitoes, 20-30 percent of the spatholobus stem, 10-18 percent of the rumex nepalensis, 15-25 percent of the agrimony, 8-15 percent of the licorice, 7-11 percent of the peanut skin and 4-17 percent of the jujube. The method has the advantages of low cost of raw materials, high efficacy of curing idiopathic thrombocytopenic purpura and significant effect of improving platelet and no toxicity and side effects.

The invention discloses medicine for treating idiopathic thrombocytopenic purpura. Scientific and reasonable compatibility is conducted on lindera aggregate, agilawood, moleplant seeds, achyranthes bidentata, ramulus euonyrni, opuntia dillenii haw, radix glycyrrhizae, astragalus membranaceus, rhizoma curculiginis, frankincense, cinnamon, herba epimedii, tuber fleeceflower stem, szechwan Chinaberry fruit, semen lepidii, Chinese polyphaga, polyporus umbellatus, fewflower wildrice fruit, radix paeoniae alba, radix ophiopogonis, prepared rehmannia root, ginger processed pinellia, caulis bambusae in taeniis, arisaema cum bile, polygala tenuifolia, semen boitae, caulis spatholobi, juncus effuses, spiderflower seed, angelica sinensis, sappanwood, pangolin, curcuma, curcuma aromatica, ligusticum wallichii, trichosanthes peel, loranthus parasiticus, codonopsis pilosula, cynanchum paniculatum, coptis chinensis, rhizoma alismatis, fiveleaf akebia fruit, uncaria, rhodiola rosea, pubescent holly root and schisandra chinensis according to the principle of monarch, minister, assistant and guide. The medicine has functions of nourishing blood and enriching blood, nourishing yin and supplementing marrow, promoting sperm production and moistening dryness, and tonifying qi and strengthening middle warmer, and has the advantages of being rapid in effect, remarkable in effect, short in treatment course, free of toxic and side effects and the like.

The invention relates to a preparation for treating thrombocytopenic purpura caused by blood stasis obstructing collaterals and a preparation method. The preparation is prepared from the following pharmaceutical raw materials in percentage by weight: 24% of radix rehmanniae recen, 24% of salvia miltiorrhiza, 15% of Chinese angelica, 24% of radix paeoniae rubra, 15% of carthamus tinctorius, 15% of cortex moutan radicis, 24% of rubia cordifolia, 24% of caulis spatholobi, 15% of herba lycopi and 10% of raw liquorice. According to the preparation, active ingredients in the pharmaceutical raw materials are extracted by a water cooking extraction method; the activity of the active ingredients are kept; the dissolubility of the active ingredients in the medicine can be improved greatly; the medicine absorption is facilitated, so that the bioavailability of the preparation can be improved. In addition, the medicine is a pure traditional Chinese medicine compound preparation, so that no toxic and/or side effects are generated after a patient takes the medicine for a long term, and the medicine is good in safety. In addition, the preparation method is simple in technology and convenient to operate.

The invention relates to a medicine for treating idiopathic thrombocytopenic purpura. The medicine is prepared from the following raw pharmaceutical materials in parts by weight: 12 parts of rubia cordifolia, 5 parts of ligusticum daucoides, 26 parts of phyllanthus urinaria, 17 parts of stringy stonecrop, 10 parts of radix Patriniae Scabrae, 18 parts of tender catchweed bedstraw herb and 7 parts of cortex dictamni. According to the medicine, the rubia cordifolia has the effects of promoting blood circulation and arresting bleeding, clearing and activating channels and collaterals and relieving cough and dispelling phlegm; the ligusticum daucoides has the effects of dispelling wind and clearing heat, descending Qi and resolving phlegm and promoting blood flow to regulate menstruation; the phyllanthus urinaria has the effects of reducing fever and causing diuresis and improving eyesight and removing stagnation of Qi; the stringy stonecrop has the effects of clearing away heat and promoting diuresis and detoxifying and promoting subsidence of swelling; the radix Patriniae Scabrae has the effects of drying dampness to stop leukorrhagia, astringing to stop bleeding and clearing away heat and toxic materials; the tender catchweed bedstraw herb has the effects of clearing away heat and toxic materials and inducing diuresis to reduce edema; the cortex dictamni has the effects of clearing heat and drying dampness, dispelling wind and arresting itching and detoxifying. The effects of purging pathogenic fire and clearing heat, promoting blood circulation and regulating Qi and nourishing Yin and tonifying kidney are achieved through jointly using the medicines. Proved by clinical trials, the medicine can be used for treating the idiopathic thrombocytopenic purpura safely and effectively.

The invention provides application of gp96 protein to preparation of a medicine for treating idiopathic thrombocytopenic purpura. The gp96 protein is heat shock protein gp96. According to the application provided by the invention, the heat shock protein gp96 is used for preparing the medicine for treating the idiopathic thrombocytopenic purpura for the first time; an experiment proves that the heat shock protein gp96 has functions of inducing regulatory T cells production, reducing spleen coefficient and improving the quantity of blood platelets. Therefore, the heat shock protein gp96 has important application value for treating autoimmune thrombocytopenic purpura and/or alleviating symptoms of the autoimmune thrombocytopenic purpura.

The present invention is based on the finding that administration of polypeptides comprising two immunoglobulin single variable domains (ISVD) against von Willebrand Factor (vWF) to human patients with an initial episode of thrombotic thrombocytopenic purpura (TTP) episode results in improved outcomes, including a faster time to platelet count response lower proportion of patients with either death, recurrence or a major thromboembolic event (TE) during the treatment period, lower recurrence rate, and prevention of refractoriness. The invention provides a polypeptide comprising two ISVD against vWF for use in treating a vWF-related disease, preferably TTP, in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.

The invention belongs to a pharmaceutical composition for treating idiopathic thrombocytopenic purpura and an application thereof. The pharmaceutical composition is prepared from codonopsis pilosula, deep-fried atractylodes macrocephala koidz, radix rehmanniae preparata, dried radix rehmanniae, cortex moutan, cornu bubali, poria cocos, licorice roots northwest origin, salviae miltiorrhizae, a red peony root, radix ophiopogonis and white peony root. The pharmaceutical composition has the advantages of being low in cost, good in effect on treatment of accurate and chronic idiopathic thrombocytopenic purpura, stable in quality control, natural, nontoxic, stable in effect and suitable for long-term medication.

The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.

The invention discloses a medicine for treatment of thrombocytopenic purpura. The medicine is prepared from 10g-20g of Fructus Silybi Mariani, 15g-30g of Radix Serratulae Chinensis, 5g-8g of Semen Vaccariae, 5g-6g of Herba Diplazii Lancei, 12g-15g of Rhizoma Alocasiae Mavrorrhize, 8g-10g of Lignum Pini Nodi, 3g-5g of Herba Diclipterae Chinensis, 4g-9g of Caulis Sinomenii, 16g-25g of Herba Cistanches and 1g-3g of Lignum Sappan. The medicine has advantages of effectiveness in treatment of thrombocytopenic purpura, quick action, no side effect and suitableness for people at different ages and indifferent genders.